Lantern Pharma Reports First Quarter 2021 Financial Results and Operational Highlights

- RADR® A.I. platform surpasses 4.6 billion datapoints curated for oncology drug development across a wide a range of tumors and drug classes - Phase 2 clinical trial for non-smokers with NSCLC (Non-Small Cell Lung Cancer) utilizing LP-300 in combination with chemotherapy scheduled to begin during third quarter of 2021 - Expanded potential indications for LP-184 to include ATRT pediatric brain cancers - Initiated preclinical development of new molecular entity, LP-284, in hematologic cancers - Strengthened intellectual property portfolio with filing of over 10 patent applications - Launched research and development collaboration leveraging RADR® for accelerating drug development for Actuate Therapeutics GSK3β drug candidate - Peer-reviewed studies of RADR® and LP-184 in BMC Bioinformatics and Oncotarget - Balance sheet cash at the end of 1Q'21 was $81.4 million, strengthened by follow-on offering in January of 2021

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here